Avidity and Cell Uptake of Integrin-Targeting Polypeptide Micelles is Strongly Shape-Dependent
Source abstract
Abstract
We describe a genetically encoded micelle for targeted delivery consisting of a diblock polypeptide with segments derived from repetitive protein motifs inspired by Drosophila melanogaster Rec-1 resilin and human tropoelastin with a C-terminal fusion of an integrin-targeting fibronectin type III domain. By systematically varying the weight fraction of the hydrophilic elastin-like polypeptide (ELP) block and molecular weight of the diblock polypeptide, we designed micelles of different morphologies that modulate the binding avidity of the human wild-type 10th fibronectin domain (Fn3) as a function of shape. We show that wormlike micelles that present the Fn3 domain have a 1000-fold greater avidity for the α v β 3 receptor compared to the monomer ligand and an avidity that is greater than a clinically relevant antibody that is driven by their multivalency. The amplified avidity of these micelles leads to significantly increased cellular internalization, a feature that may have utility for the intracellular delivery of drugs that are loaded into the core of these micelles.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cell Adhesion Molecules Research · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States
Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland
Funding
National Institute of General Medical Sciences · Division of Materials Research
References (82)
Show source-provided references
1. 10.1016/j.ces.2005.06.01910.1016/j.ces.2005.06.019 ↗
2. 10.1021/nn800072t10.1021/nn800072t ↗
3. 10.1039/C5BM00277J10.1039/C5BM00277J ↗
4. 10.1002/advs.20150022310.1002/advs.201500223 ↗
5. 10.1039/C5BM00532A10.1039/C5BM00532A ↗
6. 10.1016/j.progpolymsci.2013.07.00510.1016/j.progpolymsci.2013.07.005 ↗
7. 10.1016/j.drudis.2016.09.01310.1016/j.drudis.2016.09.013 ↗
8. 10.3390/molecules2209140110.3390/molecules22091401 ↗
9. 10.1016/S1359-6446(04)03276-310.1016/S1359-6446(04)03276-3 ↗
10. 10.1016/j.trac.2015.06.01410.1016/j.trac.2015.06.014 ↗
11. 10.1016/j.actbio.2018.04.00610.1016/j.actbio.2018.04.006 ↗
12. 10.1163/15685620677599732210.1163/156856206775997322 ↗
13. 10.1016/j.jconrel.2011.10.00510.1016/j.jconrel.2011.10.005 ↗
14. 10.1021/bm801127d10.1021/bm801127d ↗
15. 10.1039/b818869f10.1039/b818869f ↗
16. 10.1038/nrd163210.1038/nrd1632 ↗
17. 10.1016/j.tips.2009.08.00410.1016/j.tips.2009.08.004 ↗
18. 10.1016/j.jconrel.2004.08.00710.1016/j.jconrel.2004.08.007 ↗
19. 10.1016/j.molmed.2010.08.00110.1016/j.molmed.2010.08.001 ↗
20. 10.1016/B978-0-12-416020-0.00012-710.1016/B978-0-12-416020-0.00012-7 ↗
21. 10.1016/j.ejps.2012.12.00610.1016/j.ejps.2012.12.006 ↗
22. 10.2967/jnumed.116.18136210.2967/jnumed.116.181362 ↗
23. 10.1039/C7CS00316A10.1039/C7CS00316A ↗
24. 10.1098/rsta.2017.026110.1098/rsta.2017.0261 ↗
25. 10.1021/acs.nanolett.8b0355810.1021/acs.nanolett.8b03558 ↗
26. 10.2217/nnm.11.1910.2217/nnm.11.19 ↗
27. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
28. Maeda H. · Crit. Rev. Ther. Drug Carrier Syst. · 1989 · 6 · 193
29. 10.1016/S0065-2571(00)00013-310.1016/S0065-2571(00)00013-3 ↗
30. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
31. 10.1021/nl070363y10.1021/nl070363y ↗
32. 10.1021/nl052396o10.1021/nl052396o ↗
33. 10.1021/ja801442810.1021/ja8014428 ↗
34. 10.1080/1558372070145499910.1080/15583720701454999 ↗
35. 10.1038/nrd259110.1038/nrd2591 ↗
36. 10.1021/ja051977c10.1021/ja051977c ↗
37. 10.1016/j.jconrel.2007.03.02210.1016/j.jconrel.2007.03.022 ↗
38. 10.1007/s11095-008-9626-z10.1007/s11095-008-9626-z ↗
39. 10.1007/s11095-008-9562-y10.1007/s11095-008-9562-y ↗
40. 10.1038/nmat234410.1038/nmat2344 ↗
41. 10.1016/j.jconrel.2010.07.11610.1016/j.jconrel.2010.07.116 ↗
42. 10.1016/j.addr.2011.06.01610.1016/j.addr.2011.06.016 ↗
43. 10.1517/17425247.2014.95056410.1517/17425247.2014.950564 ↗
44. 10.1039/C6PY00639F10.1039/C6PY00639F ↗
45. 10.1039/C3PY01306E10.1039/C3PY01306E ↗
46. 10.1021/ma034120d10.1021/ma034120d ↗
47. 10.1016/j.jconrel.2012.05.05210.1016/j.jconrel.2012.05.052 ↗
48. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
49. 10.1039/c0nr00156b10.1039/c0nr00156b ↗
50. 10.1038/nature0408510.1038/nature04085 ↗
51. 10.1111/j.1432-1033.1997.00092.x10.1111/j.1432-1033.1997.00092.x ↗
52. 10.1021/acs.biomac.7b0058910.1021/acs.biomac.7b00589 ↗
53. 10.1097/CEJ.0b013e3280145c0010.1097/CEJ.0b013e3280145c00 ↗
54. 10.1101/cshperspect.a00647810.1101/cshperspect.a006478 ↗
55. 10.1002/ddr.2026510.1002/ddr.20265 ↗
56. 10.1111/j.1750-3639.2008.00137.x10.1111/j.1750-3639.2008.00137.x ↗
57. Wechsel H. · Anticancer research · 1999 · 19 · 1529
58. 10.1006/gyno.1996.022510.1006/gyno.1996.0225 ↗
59. 10.1158/0008-5472.CAN-06-449910.1158/0008-5472.CAN-06-4499 ↗
60. Bowditch R. D. · J. Biol. Chem. · 1994 · 269 · 1085610.1016/S0021-9258(17)34137-6 ↗
61. 10.1016/S0022-2836(03)00082-210.1016/S0022-2836(03)00082-2 ↗
62. 10.1021/bm300321n10.1021/bm300321n ↗
63. 10.1021/bi701215e10.1021/bi701215e ↗
64. 10.1021/bm901387t10.1021/bm901387t ↗
65. 10.3791/5158310.3791/51583 ↗
66. 10.1093/protein/gzi05010.1093/protein/gzi050 ↗
67. 10.1021/bi991765q10.1021/bi991765q ↗
68. 10.1021/acs.nanolett.7b0222510.1021/acs.nanolett.7b02225 ↗
69. 10.1021/nl503221p10.1021/nl503221p ↗
70. 10.1063/1.161596710.1063/1.1615967 ↗
71. 10.1016/j.bpj.2018.03.00710.1016/j.bpj.2018.03.007 ↗
72. 10.1073/pnas.060099710310.1073/pnas.0600997103 ↗
73. 10.1016/j.str.2017.09.00710.1016/j.str.2017.09.007 ↗
74. Graff C. P. · Cancer research · 2003 · 63 · 1288
75. 10.1016/j.jconrel.2016.11.03310.1016/j.jconrel.2016.11.033 ↗
76. 10.1038/s41598-017-04229-z10.1038/s41598-017-04229-z ↗
77. 10.1016/j.jconrel.2015.01.03310.1016/j.jconrel.2015.01.033 ↗
78. 10.1002/anie.20120089910.1002/anie.201200899 ↗
79. 10.1021/nl500937610.1021/nl5009376 ↗
80. 10.1016/j.jconrel.2017.11.02110.1016/j.jconrel.2017.11.021 ↗
81. 10.1021/nl500231310.1021/nl5002313 ↗
82. 10.1021/acs.macromol.5b0043110.1021/acs.macromol.5b00431 ↗